{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:40:37Z","timestamp":1794260437666,"version":"4.9.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymgme.2026.110164","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T23:42:27Z","timestamp":1779838947000},"page":"110164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The RAINBOW study: a phase 2 trial evaluating the 3-month pharmacokinetic and pharmacodynamic data and 18-month clinical and safety outcomes of nizubaglustat in GM2 gangliosidoses or Niemann\u2013Pick type C disease"],"prefix":"10.1016","volume":"148","author":[{"given":"Laura","family":"L\u00f3pez de Frutos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Almeida","family":"do Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafne D.G.","family":"Horovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Horn","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamires Silva","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Zeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Tuche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2026.110164_bb0005","first-page":"1","article-title":"Lysosomal storage diseases","volume":"2","author":"Ferreira","year":"2017","journal-title":"Transl. Sci. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110164_bb0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymgme.2026.110164_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-5-16","article-title":"Niemann\u2013Pick disease type C","volume":"5","author":"Vanier","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110164_bb0020","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/08830738060210061101","article-title":"Diagnosis and molecular characterization of non-classic forms of Tay-Sachs disease in Brazil","volume":"21","author":"Rozenberg","year":"2006","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0025","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.3390\/ijms21176213","article-title":"GM2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies","volume":"21","author":"Leal","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2026.110164_bb0030","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3390\/antiox12122021","article-title":"Niemann\u2013Pick disease type C (NPDC) by mutation of NPC1 and NPC2: aberrant lysosomal cholesterol trafficking and oxidative stress","volume":"12","author":"Lee","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.ymgme.2026.110164_bb0035","author":"Orphanet"},{"key":"10.1016\/j.ymgme.2026.110164_bb0040","author":"Orphanet"},{"key":"10.1016\/j.ymgme.2026.110164_bb0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ymgme.2021.06.011","article-title":"Estimating the prevalence of Niemann\u2013Pick disease type C (NPC) in the United States","volume":"134","author":"Burton","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110164_bb0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-018-0785-7","article-title":"International Niemann\u2013Pick disease, consensus clinical management guidelines for Niemann\u2013Pick disease type C","volume":"13","author":"Geberhiwot","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110164_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2023.101225","article-title":"The Niemann\u2013Pick type diseases \u2013 a synopsis of inborn errors in sphingolipid and cholesterol metabolism","volume":"90","author":"Pfrieger","year":"2023","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ymgme.2026.110164_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41525-023-00365-w","article-title":"Understanding the phenotypic variability in Niemann\u2013Pick disease type C (NPC): a need for precision medicine","volume":"8","author":"Las Heras","year":"2023","journal-title":"Npj Genom. Med."},{"key":"10.1016\/j.ymgme.2026.110164_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1590\/1678-4685-gmb-2016-0268","article-title":"Relative frequency and estimated minimal frequency of lysosomal storage diseases in Brazil: report from a reference laboratory","volume":"40","author":"Giugliani","year":"2017","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/acn3.51947","article-title":"Clinical and imaging predictors of late-onset GM2 gangliosidosis: a scoping review","volume":"11","author":"Godbole","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0075","doi-asserted-by":"crossref","first-page":"18787","DOI":"10.1038\/s41598-020-75919-4","article-title":"Signatures of natural selection and ethnic-specific prevalence of NPC1 pathogenic mutations contributing to obesity and Niemann\u2013Pick disease type C1","volume":"10","author":"Chiorean","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2026.110164_bb0080","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/s41431-023-01408-7","article-title":"At a glance: the largest Niemann\u2013Pick type C1 cohort with 602 patients diagnosed over 15 years","volume":"31","author":"Guatibonza Moreno","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2026.110164_bb0085","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s11033-020-05308-7","article-title":"New variants in Spanish Niemann\u2013Pick type C disease patients","volume":"47","author":"Lopez de Frutos","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ymgme.2026.110164_bb0090","article-title":"The diagnostic journey for patients with late-onset GM2 gangliosidoses","volume":"37","author":"Lopshire","year":"2023","journal-title":"Mol. Genet Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110164_bb0095","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2026.110164_bb0100","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jimd.12245","article-title":"Long-term survival outcomes of patients with Niemann\u2013Pick disease type C receiving miglustat treatment: a large retrospective observational study","volume":"43","author":"Patterson","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.110164_bb0105","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2147\/TCRM.S5777","article-title":"New therapies in the management of Niemann\u2013Pick type C disease: clinical utility of miglustat","volume":"5","author":"Wraith","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ymgme.2026.110164_bb0110","author":"United States Food and Drug Administration"},{"key":"10.1016\/j.ymgme.2026.110164_bb0115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2017.04.011","article-title":"Infantile gangliosidoses: mapping a timeline of clinical changes","volume":"121","author":"Jarnes Utz","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110164_bb0120","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1111\/ene.15871","article-title":"Efficacy and safety of miglustat in the treatment of GM2 gangliosidosis: a systematic review","volume":"30","author":"Mansouri","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2026.110164_bb0125","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1007\/s10545-009-1224-7","article-title":"Miglustat therapy in juvenile Sandhoff disease","volume":"32","author":"Tallaksen","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.110164_bb0130","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/GIM.0b013e3181a1b5c5","article-title":"Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment","volume":"11","author":"Shapiro","year":"2009","journal-title":"Genet. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.ymgme.2026.110164_bb0135","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1007\/s10545-010-9186-3","article-title":"Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up","volume":"33","author":"Masciullo","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.110164_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2025.101615","article-title":"Venglustat in GM2 gangliosidoses and related disorders: results of the AMETHIST randomized controlled and basket trials","volume":"28","author":"Tifft","year":"2026","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.110164_bb0145","unstructured":"United States Food and Drug Administration. Prescribing Information: MIPLYFFA (arimoclomol) capsules. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/214927s000lbl.pdf (Accessed January 2026)."},{"key":"10.1016\/j.ymgme.2026.110164_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109103","article-title":"Mechanistic insights into arimoclomol mediated effects on lysosomal function in Niemann\u2013Pick type C disease","volume":"145","author":"Shammas","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110164_bb0155","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/jimd.12428","article-title":"Efficacy and safety of arimoclomol in Niemann-Pick disease type C: results from a double-blind, randomised, placebo-controlled, multinational phase 2\/3 trial of a novel treatment","volume":"44","author":"Mengel","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.110164_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109189","article-title":"Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: final results of the phase 2\/3 NPC-002 48-month open-label extension trial","volume":"145","author":"Mengel","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110164_bb0165","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2310151","article-title":"Trial of N-acetyl-L-leucine in Niemann\u2013Pick disease type C","volume":"390","author":"Bremova-Ertl","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2026.110164_bb0170","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213589","article-title":"Disease-modifying, neuroprotective effect of N-acetyl-L-leucine in adult and pediatric patients with NiemannGeberhiwotPick disease type C","volume":"105","author":"Patterson","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2026.110164_bb0175","doi-asserted-by":"crossref","first-page":"fcaa148","DOI":"10.1093\/braincomms\/fcaa148","article-title":"Acetyl-leucine slows disease progression in lysosomal storage disorders","volume":"3","author":"Kaya","year":"2021","journal-title":"Brain Commun."},{"key":"10.1016\/j.ymgme.2026.110164_bb0180","author":"United States Food and Drug Administration"},{"key":"10.1016\/j.ymgme.2026.110164_bb0185","author":"IntraBio"},{"key":"10.1016\/j.ymgme.2026.110164_bb0190","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2026.110164_bb0195","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1021\/jm501181z","article-title":"Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase\/neutral glucosylceramidase inhibitors","volume":"57","author":"Ghisaidoobe","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ymgme.2026.110164_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108113","article-title":"First-in-human single-dose study of nizubaglustat, a dual inhibitor of ceramide glucosyltransferase and non-lysosomal glucosylceramidase: safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending and multiple doses in healthy adults","volume":"141","author":"Paquet Luzy","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110164_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70130","article-title":"Therapeutic effects of nizubaglustat in a mouse model of GM2 gangliosidosis","volume":"49","author":"Landskroner","year":"2026","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.110164_bb0210","author":"ClinicalTrials.gov, NCT05758922"},{"issue":"4 Suppl.","key":"10.1016\/j.ymgme.2026.110164_bb0215","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Group","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ymgme.2026.110164_bb0220","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/mds.20781","article-title":"Reliability and validity of the International Cooperative Ataxia Rating Scale: a study in 156 spinocerebellar ataxia patients","volume":"21","author":"Schmitz-Hubsch","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2026.110164_bb0225","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/mds.29255","article-title":"Temporal dynamics of the Scale for the Assessment and Rating of Ataxia in spinocerebellar ataxias","volume":"38","author":"Moulaire","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2026.110164_bb0230","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12311-012-0421-3","article-title":"Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument","volume":"12","author":"Jacobi","year":"2013","journal-title":"Cerebellum"},{"key":"10.1016\/j.ymgme.2026.110164_bb0235","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","article-title":"Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients","volume":"11","author":"Smid","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110164_bb0240","doi-asserted-by":"crossref","DOI":"10.1111\/exd.70042","article-title":"Ceramides and skin health: new insights","volume":"34","author":"Yong","year":"2025","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/biom15050608","article-title":"Topical delivery of ceramide by oil-in-water nanoemulsion to retain epidermal moisture content in dermatitis","volume":"15","author":"Zhou","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymgme.2026.110164_bb0250","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2026.110164_bb0255","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2026.110164_bb0260","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.110164_bb0265","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: the phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0270","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1038\/537S154a","article-title":"Drug development: through the barrier","volume":"537","author":"DeWeerdt","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2026.110164_bb0275","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ajh.25300","article-title":"Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: final results from the Phase 2 trial","volume":"94","author":"Lukina","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0280","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymgme.2026.110164_bb0285","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2026.110164_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043310","article-title":"Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease","volume":"7","author":"Cabrera-Salazar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2026.110164_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021758","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease","volume":"6","author":"Ashe","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2026.110164_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135889","article-title":"Reducing GBA2 activity ameliorates neuropathology in Niemann\u2013Pick type C mice","volume":"10","author":"Marques","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2026.110164_bb0305","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0091270010372387","article-title":"Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers","volume":"51","author":"Peterschmitt","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0310","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ymgme.2026.110164_bb0315","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1074\/jbc.M610304200","article-title":"Integrity and barrier function of the epidermis critically depend on glucosylceramide synthesis","volume":"282","author":"Jennemann","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2026.110164_bb0320","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5582\/irdr.2024.01056","article-title":"Evaluation of the safety and efficacy of miglustat for the treatment of Chinese patients with Niemann\u2013Pick disease type C: a prospective, open-label, single-arm, phase IV trial","volume":"13","author":"Zhang","year":"2024","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.ymgme.2026.110164_bb0325","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00592-010-0220-6","article-title":"Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas","volume":"48","author":"Hsieh","year":"2011","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2015-000190","article-title":"Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and\/or a single oral antihyperglycemic agent: a multicenter, randomized trial","volume":"4","author":"Matsushima","year":"2016","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.ymgme.2026.110164_bb0335","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13023-015-0297-7","article-title":"A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat","volume":"10","author":"Remenova","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110164_bb0340","article-title":"The juvenile gangliosidoses: a timeline of clinical change","volume":"25","author":"King","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110164_bb0345","doi-asserted-by":"crossref","first-page":"6888","DOI":"10.1007\/s00415-024-12664-y","article-title":"Assessment of the reliability, responsiveness, and meaningfulness of the scale for the assessment and rating of ataxia (SARA) for lysosomal storage disorders","volume":"271","author":"Park","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1542310","article-title":"Clinical, genotypic, and neuropsychological profile in a series of patients with Niemann\u2013Pick type C disease","volume":"16","author":"Dos Santos Mendes","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00108","article-title":"Adult-onset Niemann\u2013Pick disease type C: rapid treatment initiation advised but early diagnosis remains difficult","volume":"8","author":"Piroth","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0360","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1590\/S0100-879X2004000600001","article-title":"Biochemical characterization of the GM2 gangliosidosis B1 variant","volume":"37","author":"Tutor","year":"2004","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.ymgme.2026.110164_bb0365","doi-asserted-by":"crossref","first-page":"9452","DOI":"10.1016\/S0021-9258(19)38870-2","article-title":"Juvenile GM2 gangliosidosis caused by substitution of histidine for arginine at position 499 or 504 of the alpha-subunit of beta-hexosaminidase","volume":"265","author":"Paw","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2026.110164_bb0370","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1471-4159.1988.tb13266.x","article-title":"Mutation in GM2-gangliosidosis B1 variant","volume":"50","author":"Ohno","year":"1988","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2026.110164_bb0375","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jmb.2006.04.004","article-title":"Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis","volume":"359","author":"Lemieux","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymgme.2026.110164_bb0380","first-page":"1041","article-title":"Sequence of DNA flanking the exons of the HEXA gene, and identification of mutations in Tay-Sachs disease","volume":"49","author":"Triggs-Raine","year":"1991","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2026.110164_bb0385","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s004390100531","article-title":"Niemann-Pick type C disease: NPC1 mutations associated with severe and mild cellular cholesterol trafficking alterations","volume":"109","author":"Ribeiro","year":"2001","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2026.110164_bb0390","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/humu.10255","article-title":"Identification of 58 novel mutations in Niemann-Pick disease type C: correlation with biochemical phenotype and importance of PTC1-like domains in NPC1","volume":"22","author":"Park","year":"2003","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2026.110164_bb0395","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1086\/302620","article-title":"Mutations in NPC1 highlight a conserved NPC1-specific cysteine-rich domain","volume":"65","author":"Greer","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2026.110164_bb0400","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1590\/0004-282X20130249","article-title":"Niemann-Pick disease type C: a case series of Brazilian patients","volume":"72","author":"Lorenzoni","year":"2014","journal-title":"Arq. Neuropsiquiatr."}],"updated-by":[{"DOI":"10.1016\/j.ymgme.2026.110164","type":"removal","label":"Removal","source":"publisher","updated":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000}}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226004476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226004476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:08:10Z","timestamp":1785877690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226004476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1096719226004476"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110164","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The RAINBOW study: a phase 2 trial evaluating the 3-month pharmacokinetic and pharmacodynamic data and 18-month clinical and safety outcomes of nizubaglustat in GM2 gangliosidoses or Niemann\u2013Pick type C disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110164"}}